IMMUNITYBIO INC (IBRX) is drawing unusual attention today. Our newswire has captured 1 story on IBRX across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
ImmunityBio (IBRX) shares rose 7.37% to $10.64, driven by the announcement that founder and Executive Chairman Dr. Patrick Soon-Shiong will participate in a virtual fireside chat at the Piper Sandler Virtual Oncology Symposium on October 16, 2026. The company stated it plans to discuss the progress of its lead drug, ANKTIVA, during the event. This catalyst followed recent regulatory approvals and strong quarterly results, contributing to a significant upward move in the stock price.
ImmunityBio confirmed that Dr. Soon-Shiong will join the Piper Sandler Virtual Oncology Symposium to highlight the development of ANKTIVA. The company emphasized that the initiative aligns with its "Immunotherapy 2.0" vision, which combines immune treatments, diagnostics, and monitoring to help prevent cancer recurrence. This announcement comes shortly after the drug received approval in the United Arab Emirates for non-small cell lung cancer, a decision based on the QUILT-3.055 trial which showed a 14.6-month median overall survival in checkpoint-refractory patients. Additionally, the company recently achieved the world's broadest bladder cancer approval for ANKTIVA.
In its most recent quarterly report, ImmunityBio reported adjusted earnings per share of $(0.08), which beat the estimate of $(0.09). Sales came in at $51.240 million, exceeding the $49.700 million estimate. These financial results, combined with the upcoming symposium appearance, have fueled renewed interest in the stock.
The stock opened at $9.96 and reached a session high of $10.67 at 10:10 AM ET before settling near $10.55. Volume stood at 3.1 million shares, which is 0.3 times the 3-month daily average. The company has a market capitalization of $10.3 billion and remains unprofitable with a trailing twelve-month EPS of -0.99. However, revenue has grown 192.9% over the trailing twelve months. The 52-week range spans from $1.95 to $12.43. Over the last eight sessions, the stock has climbed 12.2% from $8.84 to $9.91. Recent insider activity shows two sales totaling $1.1 million in the last 90 days, with no purchases recorded.
Investors will look to the October 16, 2026, fireside chat for further details on ANKTIVA's clinical progress and the company's broader immunotherapy strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.
IMMUNITYBIO INC (IBRX) is drawing unusual attention today. Our newswire has captured 1 story on IBRX across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 64/100). The most recent driver: "IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave" (Stocktwits News).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of IBRX coverage reads 64/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on IBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IBRX move explainers: 2026-10-09 · 2026-10-02 · 2026-10-01 · 2026-09-30 · 2026-08-26 · 2026-08-25 · 2026-07-11